ClinicalTrials.gg
Not yet recruitingNCT07846579CLEARUpdated Sep 29, 2026

Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial)

A Phase 4 interventional study of Tamsulosin hydrochloride 0.2 mg and Placebo in Benign Prostatic Hyperplasia, sponsored by Shanghai East Hospital. Not yet recruiting. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Shanghai East Hospital · Phase 4, Interventional, and Treatment

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Study summary

After surgery for benign prostatic hyperplasia (BPH) that physically removes the prostatic transition zone (such as TURP or laser enucleation), many men are routinely sent home with a 2- to 4-week prescription of an alpha-blocker (tamsulosin) to prevent urinary retention, even though the tissue targeted by the drug has been removed. Alpha-blockers can cause blood-pressure drops upon standing, fainting, and falls in older men.

In this study, men who have successfully undergone BPH surgery and passed an initial voiding trial are randomly assigned to take either tamsulosin or an identical-looking placebo capsule once daily for 30 days. The study tests whether stopping the drug immediately does not increase the risk of needing a catheter again (non-inferiority), and whether stopping it reduces dizziness, fainting, and falls (superiority).

Read the detailed description

The CLEAR trial is an investigator-initiated, multicentre, double-blind, placebo-controlled, randomised clinical trial with a hierarchical co-primary endpoint design and a Bayesian adaptive group-sequential plan. Eligible participants are men aged 50 years or older with BPH refractory to medical therapy who have used an oral alpha-1-blocker daily for at least 4 weeks before surgery, have successfully completed anatomical de-obstruction surgery (resection or enucleation), and have passed an initial trial without catheter on postoperative day 2.

At the time of successful catheter removal (Day 0), participants are randomised 1:1 via a central interactive web-response system, using covariate-adaptive minimisation stratified by clinical centre, surgical modality (resection vs enucleation), and concurrent antihypertensive use, to receive tamsulosin hydrochloride 0.2 mg or an organoleptically identical placebo once daily for 30 days.

The trial first tests the non-inferiority of placebo for the rate of unplanned re-catheterisation due to acute postoperative urinary retention within 30 days (objective criteria: inability to void, post-void residual >=300 mL on bladder scan, refractory to 2-hour conservative measures; non-inferiority margin 5.0%). Conditional on non-inferiority being established, it then tests the superiority of placebo for the composite incidence of symptomatic orthostatic hypotension, presyncope, syncope, and falls within 30 days, captured by a standardised Active Stand Test and twice-weekly electronic patient-reported outcomes, and adjudicated by an independent, blinded Clinical Event Committee. Unblinded interim analyses are performed by the independent Data and Safety Monitoring Board when 200 and 300 participants have completed the Day 30 assessment, with early stopping guided by the Bayesian predictive probability of success (thresholds 0.95 for early success and 0.10 for futility).

Secondary endpoints include functional recovery (IPSS, Qmax), unscheduled healthcare utilisation, severe haematuria/clot retention, medication adherence, and a prospective health-economic evaluation (EQ-5D-5L, ICER).

A prespecified blinded sample-size re-estimation, based on the pooled (arm-agnostic) event rate at the first interim analysis, allows maximum enrolment to be increased from 400 up to 600 participants to preserve conditional power, without unblinding.

02

Conditions studied

  • Benign Prostatic Hyperplasia

Keywords

  • deprescribing
  • tamsulosin
  • alpha-1 adrenoceptor antagonist
  • benign prostatic hyperplasia
  • postoperative urinary retention
  • orthostatic hypotension
  • falls
03

In context

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

This study's planned enrollment of 400 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.

Browse Prostatic Hyperplasia studies →

Lead sponsor

Shanghai East Hospital is the lead sponsor of 95 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult males aged >=50 years;
  2. Documented diagnosis of benign prostatic hyperplasia/benign prostatic obstruction (BPH/BPO) to medical therapy, or with surgical indications (e.g., recurrent urinary retention, repeated gross haematuria, bladder calculi);
  3. Successful completion of an anatomical de-obstruction surgery (e.g., monopolar/bipolar TURP, HoLEP, ThuLEP) ;
  4. Continuous daily use of an oral alpha-1-adrenoceptor antagonist for at least 4 weeks immediately prior to surgery;
  5. Successful initial trial without catheter (TWOC) on postoperative day 2;
  6. Written and ability to comply with ePRO monitoring.

Exclusion criteria

Exclusion Criteria:

  1. Resection/enucleation deemed "incomplete" or "suboptimal" by the primary surgeon, or severe intraoperative complications (e.g., capsular perforation requiring prolonged traction, significant rectal injury, massive haemorrhage necessitating continuous irrigation beyond 48 hours);
  2. Diagnosed neurogenic bladder (Parkinson's disease, multiple sclerosis, severe spinal cord injury, advanced diabetic cystopathy);
  3. Urodynamically proven detrusor underactivity/hypocontractile bladder prior to surgery;
  4. urethral stricture or bladder neck contracture requiring separate reconstruction;
  5. Documented history of recurrent unexplained syncope or severe symptomatic orthostatic hypotension prior to surgery;
  6. Inability to ambulate independently or perform the Active Stand Test;
  7. Requirement for continuous postoperative use of anticholinergics or beta-3 agonists;
  8. Continuation of 5-alpha-reductase inhibitors postoperatively against protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Deprescribing (Placebo)

    Organoleptically identical placebo capsule, one capsule orally once daily (after dinner or at bedtime) for 30 days, starting on the day of successful catheter removal (Day 0).

    Drug: Placebo

  • Active comparator
    Standard of Care (Tamsulosin)

    Tamsulosin hydrochloride 0.2 mg sustained-release capsule, one capsule orally once daily for 30 days, starting on the day of successful catheter removal (Day 0). 0.2 mg once daily is the approved standard dosage in China and several Asian populations.

    Drug: Tamsulosin hydrochloride 0.2 mg

Interventions

  • As per Arm B

  • DrugPlacebo

    Matching placebo capsule, visually and organoleptically indistinguishable from the active capsules; identical packaging and labelling with a unique medication ID number.

06

What researchers measure

Primary outcomes

  1. Rate of unplanned re-catheterisation due to acute postoperative urinary retention (POUR)

    Proportion of participants requiring unplanned re-catheterisation meeting ALL objective criteria: (i) complete inability to void spontaneously with suprapubic pain/distress; (ii) post-void residual \>=300 mL on bladder ultrasound; (iii) failure of conservative measures over a 2-hour observation period. Re-catheterisation for clot retention is not counted. Analysed as the absolute risk difference (placebo minus tamsulosin); non-inferiority declared if the upper bound of the two-sided 95% CI is \< +5.0%, in both the ITT and per-protocol populations.

    Time frame: Day 0 (catheter removal) through Day 30

  2. Composite incidence of symptomatic orthostatic hypotension, presyncope, syncope, and falls

    Composite of: (i) orthostatic hypotension on the standardised Active Stand Test (systolic drop \>=20 mmHg or diastolic drop \>=10 mmHg within 3 minutes of standing, or reproduction of cerebral hypoperfusion symptoms); (ii) self-reported presyncope/syncope captured by twice-weekly ePRO; (iii) falls (WHO definition). All clinical events adjudicated by an independent, blinded Clinical Event Committee. Tested for superiority only if non-inferiority of the efficacy endpoint is established (hierarchical gatekeeping).

    Time frame: Day 0 through Day 30

Secondary outcomes

  1. Change in International Prostate Symptom Score (IPSS)

    Absolute change and total score, compared between arms

    Time frame: Baseline (preoperative) to Day 30

  2. Change in maximal urinary flow rate (Qmax)

    Uroflowmetry, compared between arms.

    Time frame: Baseline to Day 30

  3. Rate of unscheduled healthcare utilisation

    Emergency department or unscheduled clinic visits for any urological cause

    Time frame: Baseline to Day 30

  4. Incidence of severe macroscopic haematuria / clot retention

    Haemorrhagic events requiring bladder washout, manual clot evacuation, re-initiation of continuous bladder irrigation, or blood transfusion.

    Time frame: Day 0 through Day 30

  5. Medication adherence

    Proportion of participants consuming \>=80% and \<=120% of dispensed capsules (mandatory pill count)

    Time frame: Day 30

  6. Health-related quality of life (EQ-5D-5L)

    Utility scores mapped to the Chinese value set

    Time frame: Baseline and Day 30

  7. Incremental cost-effectiveness ratio (ICER)

    Cost per QALY gained for deprescribing vs routine continuation, from healthcare-system and societal perspectives.

    Time frame: Day 0 through Day 30 (extrapolated to 1 year by decision-analytic modelling)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data and the signed statistical analysis plan will be available upon reasonable request to qualified academic researchers whose proposed analyses have been approved by an independent review committee.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning after publication of the primary trial results.

Access criteria: Proposals will be reviewed by the Trial Steering Committee; access requires approval and a data-access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 28 phase 4 interventional studies under Prostatic Hyperplasia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Feb 1, 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846579
Lead sponsor
Shanghai East Hospital
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

biming He
Contact
190589109@qq.com
15502139410
haifeng wang
Contact
kuohaiandrew2000@vip.sina.com
86-13681750891
haifeng wang
study chair · Changhai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion